SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Peer-reviewed published articles

17 Jan 2013 07:00

RNS Number : 7246V
Tristel PLC
17 January 2013
 



Tristel plc

("Tristel")

 

Peer-reviewed published articles supporting Tristel's technology and products

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces the publication of two articles in peer-reviewed journals that describe the benefits of Tristel products.

 

The first is titled "Guidelines for Reprocessing Non-lumened Heat-Sensitive Ear/Nose/Throat Endoscopes" and has been published in The Laryngoscope, the journal of The American Laryngological, Rhinological and Otological Society (Laryngoscope , 122:1708-1718, 2012). The article proposes the standardisation of disinfection procedures for ENT endoscopes and reviews a number of technologies including Tristel's Wipes System, Stella decontamination system and Shine automated washer-disinfector. 

 

The second publication is of a study undertaken in the Prince of Wales Hospital, Hong Kong, and is titled "Transvaginal ultrasound probe contamination by the human papillomavirus in the emergency department" (Emergency Medicine Journal, July 2012). The study revealed the prevalence of human papillomavirus (HPV) on the ultrasound equipment used routinely in the hospital and indicated that existing disinfection methods were inappropriate. The hospital has adopted the Tristel Wipes System to improve its decontamination process. 

 

Tristel CEO, Paul Swinney, commented: "We believe the Wipes System is now gaining recognition as the "gold standard" for ENT endoscopes in countries where it has been approved for use, which include all those in the European Community, Australia and many countries in the Far East. Whilst we have not attempted to register the Wipes System in the United States, its inclusion in The Laryngoscope review of decontamination methodologies, which is the most widely read journal for ENT worldwide, is a significant benefit to the marketing of our product.

 

"A second area in the hospital where the Wipes System is achieving rapid uptake in the United Kingdom and Australia is ultrasound. The Prince of Wales study joins a growing body of scientific evidence that existing methods of disinfecting intra-vaginal and rectal ultrasound probes are inadequate. The Wipes System is considered to be a more effective method of disinfection. In terms of patient procedures, and therefore disinfectant use, ultrasound is as large a market as digestive and respiratory medicine where almost all the attention of the infection control market has been focused for the past twenty years. Our product strategy of focusing on the smaller non-lumened instruments used in ENT and ultrasound positions us well for continued growth in this area."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Lianne Cawthorne

Mob: 07854 391 303 or lianne.cawthorne@walbrookpr.com

finnCap

Tel: 020 7600 1658

Geoff Nash (Corporate Finance)

Charlotte Stranner (Corporate Finance)

Simon Starr (Corporate Broking)

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASFUFMMFDSEDF
Date   Source Headline
21st Aug 20079:32 amRNSAIM Rule 26 & Adviser Name
3rd Aug 20074:27 pmRNSDirector Declaration
6th Jul 20072:54 pmRNSNotifiable Interest
29th Jun 200711:44 amRNSBoard appointment-Replacement
29th Jun 20077:03 amRNSBoard appointment
27th Jun 20077:00 amRNSTrading Statement
30th Apr 20072:40 pmRNSTotal Voting Rights
27th Apr 20073:18 pmRNSNotifiable Interest
27th Apr 20073:16 pmRNSNotifiable Interest
27th Apr 20073:15 pmRNSNotifiable Interest
27th Apr 20073:14 pmRNSNotifiable Interest
11th Apr 20077:01 amRNSCompletion of assignment
20th Mar 20077:01 amRNSGrant of Patent
14th Mar 20073:52 pmRNSDividend Pay Date Amendment
19th Feb 20077:01 amRNSInterim Results
13th Feb 20077:01 amRNSNotice of Results
3rd Jan 20077:00 amRNSGrant of Patents
28th Dec 200610:30 amRNSTotal Voting Rights
8th Dec 20067:00 amRNSDirector/PDMR Shareholding
15th Nov 200611:59 amRNSAGM Statement
15th Nov 200611:55 amRNSResult of AGM
1st Nov 20067:01 amRNSDirector/PDMR Shareholding
24th Oct 20062:30 pmRNSDividend Declaration
23rd Oct 20067:01 amRNSFinal Results
12th Oct 20067:01 amRNSNotice of Results
29th Aug 20067:01 amRNSAcquisition
9th Aug 200612:00 pmRNSDirector/PDMR Shareholding
9th Aug 20067:00 amRNSAcquisition update
16th Jun 20063:39 pmRNSDirector/PDMR Shareholding
6th Jun 20067:01 amRNSAcquisition update
26th May 20068:56 amRNSDirector/PDMR Shareholding
25th May 20068:21 amRNSDirector/PDMR Shareholding
24th May 200611:10 amRNSDirector/PDMR Shareholding
23rd May 20067:03 amRNSAcquisition & Trading Update
13th Feb 20067:01 amRNSInterim Results
6th Feb 200611:10 amRNSNotice of Results
23rd Dec 200512:22 pmRNSGrant of Options
15th Nov 200511:36 amRNSAGM Statement
7th Oct 20057:00 amRNSDirector/PDMR Shareholding
5th Oct 20053:29 pmRNSNotice of AGM
4th Oct 20055:18 pmRNSDividend payment date
3rd Oct 20057:00 amRNSFinal Results
19th Sep 20054:08 pmRNSNotice of Results
4th Jul 20057:00 amRNSGrant of Patent

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.